PME.ASX: Interview with Dr Sam Hupert - CEO of Pro Medicus Ltd

Interview with Dr Sam Hupert - CEO of Pro Medicus Ltd

Stock	Pro Medicus Ltd (PME.ASX)
Release Time	1 Jun 2026, 8:23 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Interview with Pro Medicus CEO Dr. Sam Hupert

Key Points

Contract wins with BILH, U Maryland, and Tidal Health
AI impact on technology companies
Implementations and revenue recognition
Cardiology adoption and market trends
Investment in 4D Medical

Full Summary

In an interview, Pro Medicus CEO Dr. Sam Hupert discusses recent contract wins with Beth Israel Lahey Health, U Maryland, and Tidal Health, emphasizing the significance of these deals for the company's market presence. He addresses the impact of AI on technology companies, noting that while the market reacted negatively, recent wins and renewals suggest a potential shift. Dr. Hupert also explains the timing of revenue recognition from large implementations, highlighting that most revenue will flow from FY27 onwards. Additionally, he comments on the increasing adoption of cardiology services, driven by the demand for unified imaging platforms. Lastly, he mentions the company's investment in 4D Medical and potential future collaborations.

Guidance

FY26 revenue to be over double FY24, with most revenue from large implementations in FY27

Outlook

Pro Medicus expects a material step-up in transaction volumes in the first half of FY27, with significant contributions from Trinity, U Colorado, and BayCare.